D
Dong-Ping Guo
Publications - 3
Citations - 106
Dong-Ping Guo is an academic researcher. The author has contributed to research in topics: Vaccination & Randomized controlled trial. The author has an hindex of 2, co-authored 2 publications receiving 41 citations.
Papers
More filters
Journal ArticleDOI
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial
You-Lin Qiao,Ting Wu,Rong-Cheng Li,Yuemei Hu,Lihui Wei,Changgui Li,Wen Chen,Shoujie Huang,Fang-Hui Zhao,Mingqiang Li,Qin-Jing Pan,Xun Zhang,Qing Li,Ying Hong,Chao Zhao,Wen-hua Zhang,Yanping Li,Kai Chu,Mei Li,Yun-Fei Jiang,Juan Li,Hui Zhao,Zhijie Lin,Xuelian Cui,Wen-Yu Liu,Caihong Li,Dong-Ping Guo,Li-Dong Ke,Xin Wu,Jie Tang,Guo-Qi Gao,Ba-Yi Li,Bin Zhao,Fengxian Zheng,Cui-Hong Dai,Meng Guo,Jun Zhao,Yingying Su,Junzhi Wang,Fengcai Zhu,Shaowei Li,Huirong Pan,Yimin Li,Jun Zhang,Ningshao Xia +44 more
TL;DR: The Escherichia coli-produced HPV- 16/18 vaccine is well tolerated and highly efficacious against HPV-16/18 associated high-grade genital lesions and persistent infection in women.
Journal ArticleDOI
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
Fang-Hui Zhao,Yuemei Hu,Li-Hui Wei,Ming-Qiang Li,Wei Huang,Wen Chen,Shoujie Huang,Qin-Jing Pan,Xun Zhang,Ying Hong,Chao Zhao,Qing Li,Kai Chu,Yunqiu Jiang,Mingzhu Li,Jie Tang,Caihong Li,Dong-Ping Guo,Li-Dong Ke,Xinyoung Wu,Xing-Mei Yao,Jianhang Nie,Bizhen Lin,Yuqian Zhao,Meng Guo,Junhong Zhao,Fengxin Zheng,Xiao-Jian Xu,Qiu-fen Zhang,Guang Sun,Fengcai Zhu,Shaowei Li,Yimin Li,Huirong Pan,Jun Zhang,Yu Qiao,Ningshao Xia +36 more
TL;DR: Wang et al. as mentioned in this paper reported the long-term efficacy and safety after 66 months of follow-up of a phase 3 trial of the E coli-produced bivalent vaccine against high grade genital lesions and persistent infection.
Journal ArticleDOI
Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18–45 years enrolled in a clinical trial
Li-hui Wei,Yingying Su,Yuemei Hu,Rongcheng Li,Wen Chen,Qin-Jing Pan,Xun Zhang,Fang-Hui Zhao,Yuqian Zhao,Qing Li,Ying Hong,Chao Zhao,Mingqiang Li,Wenyu Liu,Caihong Li,Dong-Ping Guo,Li-Dong Ke,Bizhen Lin,Zhijie Lin,Shu Chen,Wei Sheng,Zizheng Zheng,Sijie Zhuang,Fengcai Zhu,Huirong Pan,Yimin Li,Shoujie Huang,Jun Zhang,You-Lin Qiao,Ting Wu,Ningshao Xia +30 more
TL;DR: The majority of Chinese women aged 18-26 years and 27-45 years were naïve to both HPV-16 and HPV-18 and would thus derive full benefit from bivalent HPV vaccination.